NASDAQ · ECOR
electroCore, Inc.
$8.11-$0.31 (-3.68%)
electroCore, Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.14% below the high.
Loading market information…
NASDAQ · HYPD · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Hyperion DeFi, Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.95% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Hyperion DeFi, Inc.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of $2.31. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Hyperion DeFi, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Hyperion DeFi, Inc. is a U.S. publicly listed company that is building a long-term strategic treasury of HYPE, the native token of the Hyperliquid blockchain. The company's primary objective is to provide shareholders with streamlined access to the Hyperliquid ecosystem. Shareholders gain compounding exposure to HYPE through the token's native staking yield and additional revenues from its on-chain utility. The company also continues the development of its proprietary Optejet User Filled Device for ophthalmic applications, reflecting its transformation from its prior focus on ophthalmic technology.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:12 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 19, 2025 | -$1.59+75.16% vs estimate | $14.72K-98.53% vs estimate |
|---|
| Q3 2024 | Nov 12, 2024 | -$8.80+12.4% vs estimate | $1.63K-98.94% vs estimate |
|---|
| Q2 2024 | Aug 12, 2024 | -$16.80-40.0% vs estimate | $22.63K-97.53% vs estimate |
|---|
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $9.83.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$8.11-$0.31 (-3.68%)
electroCore, Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.14% below the high.
$3.42-$0.06 (-1.72%)
Verrica Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 65.18% below the high.
$1.30+$0.04 (+3.17%)
Myomo, Inc.’s quoted price sits in the upper half of its reported 52-week range, 31.22% below the high.
$2.04$0.00 (0.0%)
Mural Oncology plc’s quoted price sits in the lower half of its reported 52-week range, 56.96% below the high.
$0.53-$0.01 (-1.26%)
Jasper Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.55% below the high.
$1.72-$0.19 (-9.95%)
Modular Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.79% below the high.
$4.20+$0.17 (+4.22%)
P3 Health Partners Inc.’s quoted price sits in the lower half of its reported 52-week range, 75.13% below the high.
$0.97+$0.11 (+12.96%)
NeuroOne Medical Technologies Corporation’s quoted price sits in the lower half of its reported 52-week range, 84.15% below the high.
